Orchid Pharma Limited

BSE: ORCHPHARMA524372ISIN INE191A01027

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹877.55+34.80 (+4.13%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,142.65
52W low: ₹471.30
Off 52W high: -23.20%
1M return: -9.23%
3M return: -11.39%
6M return: +32.34%
1Y return: +11.18%
20D avg volume: 5,281
50 DMA: ₹959.85
200 DMA: ₹813.67

Key ratios Consolidated

Market cap: ₹5,255 Cr
Current price: ₹877.55
52W high / low: ₹1,142.65 / ₹471.30
Face value: ₹10.00
P/E: 490.00
P/B: —
EPS (TTM): ₹1.79
Book value / share: —
ROE: —
ROCE: 2.10%
Operating margin: —
Net margin: —
Debt / equity: 0.28
Net debt: ₹350.47 Cr
Interest cover: 2.59
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 85.9 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	304.17	368.33	207.27	193.52	172.93	237.48	217.34	222.70	244.41	217.10	220.59	198.75
	1.83	7.77	5.61	10.77	11.45	3.90	8.49	7.52	7.57	13.36	7.62	8.36
	306.00	376.10	212.88	204.30	184.38	241.38	225.83	230.22	251.98	230.46	228.21	207.11
	303.35	351.04	217.91	207.63	170.67	222.28	203.38	204.31	223.86	200.08	198.01	187.09
	206.42	209.84	118.97	112.27	110.16	136.94	142.02	153.72	152.77	156.47	135.62	117.86
	0.61	0.48	0.25	0.17	0.79	1.24	1.37	—	—	—	—	—
	28.04	27.62	24.13	24.85	21.61	22.24	22.06	20.06	22.00	17.57	19.14	17.56
	2.23	3.09	3.18	3.73	3.26	3.92	3.80	3.33	3.50	3.47	3.54	3.81
	10.95	10.90	9.03	8.90	8.65	8.87	8.61	8.62	8.44	8.42	9.27	7.84
	57.83	65.11	38.43	37.64	38.28	49.24	44.13	41.14	39.66	42.49	44.12	35.55
	2.65	25.07	-5.03	-3.33	13.71	19.09	22.45	25.90	28.12	30.38	30.19	20.02
	0.00	0.54	-7.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	2.65	24.85	-12.15	-3.33	13.71	19.09	22.45	25.90	28.12	30.38	30.19	20.02
	0.07	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.15	3.12	0.00	0.00
	3.22	25.84	-12.61	-5.72	14.91	22.30	20.77	27.24	29.35	32.96	29.43	19.80
	0.54	4.69	-2.49	-1.13	2.94	4.40	4.10	5.37	5.79	6.81	6.18	4.30
Key metrics
	15.83	38.84	0.06	9.30	25.62	31.88	34.86	37.85	40.06	42.27	43.00	31.67
	5.20%	10.50%	0.00%	4.80%	14.80%	13.40%	16.00%	17.00%	16.40%	19.50%	19.50%	15.90%
	1.10%	7.00%	-6.10%	-3.00%	8.60%	9.40%	9.60%	12.20%	12.00%	15.20%	13.30%	10.00%
	—	1.70%	—	0.00%	—	1.60%	—	—	—	—	—	—
	75.90%	55.10%	-4.60%	-13.10%	-29.20%	9.40%	-1.50%	12.10%	—	—	—	—
	-78.40%	15.90%	-160.70%	-121.00%	-49.20%	-32.30%	-29.40%	37.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,073	1,233	921.93	819.37	665.90	559.56
	25.98	36.42	27.48	30.86	19.43	9.00
	1,099	1,269	949.40	850.23	685.33	568.56
	1,080	1,251	853.84	758.29	669.29	628.98
	647.50	771.39	585.46	528.35	406.10	340.62
	1.51	1.69	2.61	—	—	—
	104.64	117.66	86.36	69.64	65.35	63.28
	12.23	13.26	14.54	16.36	32.23	32.01
	39.78	43.25	34.55	33.24	54.79	87.03
	199.01	237.09	174.17	154.59	132.31	133.11
	19.36	27.59	95.56	91.94	16.04	-60.42
	-6.57	-7.33	0.00	0.00	39.21	0.00
	12.02	21.02	95.56	91.94	55.25	-60.42
	0.07	-0.19	-0.19	3.12	0.00	0.00
	10.73	20.55	99.66	92.17	46.32	-1.95
	1.61	4.05	19.65	19.06	13.01	-0.48
Key metrics
	64.03	77.53	144.65	141.54	142.27	58.62
	5.97%	6.30%	15.70%	17.30%	21.40%	10.50%
	1.00%	1.70%	10.80%	11.20%	7.00%	-0.30%
	—	2.10%	7.90%	—	—	—
	26.20%	33.70%	12.50%	23.00%	19.00%	—
	-87.41%	-79.40%	8.10%	99.00%	2,475.40%	—
	—	-282.38	-130.89	—	—	—
	—	4.92	0.19	—	—	—
	—	0.28	0.14	—	—	—
	—	350.47	153.13	—	—	—
	—	85.9	137.0	—	—	—
Balance sheet
	—	1,911	1,688	—	—	—
	—	683.61	807.42	—	—	—
	—	7.01	21.11	—	—	—
	—	263.87	241.83	—	—	—
	—	256.41	326.37	—	—	—
	—	76.67	53.76	—	—	—
	—	613.22	631.59	—	—	—
	—	229.90	222.09	—	—	—
	—	278.97	285.57	—	—	—
	—	357.48	174.24	—	—	—
	—	29.75	42.60	—	—	—
	—	327.73	131.64	—	—	—
	—	1,288	1,267	—	—	—
Cash flow
	—	101.20	19.22	—	—	—
	—	-285.27	-26.93	—	—	—
	—	169.98	25.22	—	—	—
	—	383.58	150.11	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	304.17	368.33	207.27	193.52	172.93	237.48	217.34	222.70	244.41	217.10	220.59	198.75
	10.05	13.73	10.59	15.43	15.93	6.26	9.94	7.96	7.77	12.88	7.44	8.18
	314.22	382.06	217.86	208.95	188.86	243.74	227.28	230.66	252.18	229.99	228.03	206.94
	302.28	349.17	216.57	206.72	170.66	215.89	203.37	205.04	223.07	200.03	197.48	186.70
	206.42	209.84	118.97	112.27	110.16	136.94	142.02	153.72	152.77	156.47	135.62	117.86
	0.61	0.48	0.25	0.17	0.79	1.24	1.37	—	—	—	—	—
	26.76	26.33	22.88	24.05	21.61	22.24	22.06	20.69	21.37	17.57	18.66	17.19
	2.21	3.08	3.17	3.73	3.26	3.98	3.79	3.30	3.47	3.45	3.54	3.80
	10.90	11.18	8.97	8.79	8.65	8.76	8.61	8.63	8.44	8.40	9.27	7.84
	58.11	64.27	38.40	37.64	38.27	42.89	44.13	41.27	39.53	42.49	44.07	35.53
	11.94	30.07	1.29	2.23	18.20	27.85	23.91	25.63	29.10	29.96	30.55	20.24
	0.00	0.54	-7.11	0.00	0.00	0.00	—	—	—	—	—	—
	11.94	32.66	-5.82	2.23	18.20	27.85	23.91	25.63	29.10	29.96	30.55	20.24
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	3.23	—	—
	11.94	32.66	-5.82	2.23	18.20	27.85	23.91	25.63	29.10	33.19	30.55	20.24
	1.99	6.03	-1.15	0.44	3.59	5.49	4.71	5.05	5.74	6.86	6.42	4.40
Key metrics
	25.05	46.92	6.32	14.75	30.11	40.59	36.31	37.56	41.01	41.81	43.36	31.88
	8.20%	12.70%	3.00%	7.60%	17.40%	17.10%	16.70%	16.90%	16.80%	19.30%	19.70%	16.00%
	3.90%	8.90%	-2.80%	1.20%	10.50%	11.70%	11.00%	11.50%	11.90%	15.30%	13.80%	10.20%
	—	2.30%	—	0.40%	—	2.20%	—	—	—	—	—	—
	75.90%	55.10%	-4.60%	-13.10%	-29.20%	9.40%	-1.50%	12.10%	—	—	—	—
	-34.40%	17.30%	-124.30%	-91.30%	-37.50%	-16.10%	-21.70%	26.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,073	1,233	921.93	819.37	665.90	556.97
	49.80	56.49	31.93	30.39	19.43	9.00
	1,123	1,289	953.86	849.76	685.33	565.98
	1,075	1,247	847.37	758.23	669.29	618.75
	647.50	771.39	585.46	528.35	406.10	336.80
	1.51	1.69	2.61	—	—	—
	100.02	114.32	86.36	69.64	65.35	60.21
	12.19	13.24	14.54	16.33	32.23	32.01
	39.84	43.36	34.44	33.22	54.79	87.02
	198.42	236.21	167.81	154.59	132.31	125.44
	45.53	51.78	106.48	91.52	16.04	-52.77
	-6.57	-6.57	0.00	—	39.21	—
	41.01	45.21	106.48	91.52	55.25	-52.77
	0.00	0.00	0.00	3.23	—	—
	41.01	45.21	106.48	94.75	54.19	-4.81
	7.31	8.91	20.99	19.59	13.54	-1.18
Key metrics
	93.04	101.81	155.46	141.07	142.27	66.26
	8.67%	8.30%	16.90%	17.20%	21.40%	11.90%
	3.82%	3.70%	11.50%	11.60%	8.10%	-0.90%
	—	3.70%	8.30%	—	—	—
	26.20%	33.70%	12.50%	23.00%	19.60%	—
	-57.10%	-57.50%	12.40%	74.80%	1,226.60%	—
	—	-47.13	-41.06	—	—	—
	—	2.62	0.26	—	—	—
	—	0.13	0.13	—	—	—
	—	178.34	158.37	—	—	—
	—	106.8	157.4	—	—	—
Balance sheet
	—	1,750	1,697	—	—	—
	—	635.99	786.39	—	—	—
	—	1.24	15.87	—	—	—
	—	263.87	241.83	—	—	—
	—	256.41	326.37	—	—	—
	—	46.37	48.45	—	—	—
	—	591.69	612.12	—	—	—
	—	159.57	170.48	—	—	—
	—	182.80	237.47	—	—	—
	—	179.58	174.24	—	—	—
	—	0.96	42.60	—	—	—
	—	178.62	131.64	—	—	—
	—	1,370	1,324	—	—	—
Cash flow
	—	118.64	27.48	—	—	—
	—	-125.37	-37.35	—	—	—
	—	-7.90	25.44	—	—	—
	—	165.77	68.54	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +22.79%
Sales CAGR 5Y: —
Profit CAGR 3Y: -5.86%
Profit CAGR 5Y: —
Sales YoY (TTM): +26.20%
Profit YoY (TTM): -57.10%

Consolidated

Sales CAGR 3Y: +22.79%
Sales CAGR 5Y: —
Profit CAGR 3Y: -23.73%
Profit CAGR 5Y: —
Sales YoY (TTM): +26.20%
Profit YoY (TTM): -87.41%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 74.49%

Quarter	September 2026	June 2026
Promoter %	74.49%	74.49%

Holder	Type	Holding	Previous	Change
Triveni Trust	Promoter	32.62%	32.62%	0.00%
MANISH DHANUKA	Promoter	10.94%	10.94%	0.00%
Pushpa Dhanuka Trust	Promoter	9.68%	9.68%	0.00%
QUANT MUTUAL FUND - QUANT SMALL CAP FUND	Public	5.79%	5.79%	0.00%
MAMTA DHANUKA	Promoter	5.20%	5.20%	0.00%
ARJUN DHANUKA	Promoter	4.82%	4.82%	0.00%
KOTAK MAHINDRA TRUSTEE CO LTD AND 6 OTHERS WITH SAME PAN	Public	3.99%	—	—
UMA DHANUKA	Promoter	3.15%	3.15%	0.00%
UTI VALUE FUND AND 3 OTHERS WITH SAME PAN	Public	3.09%	—	—
PUSHPA DHANUKA	Promoter	3.09%	3.09%	0.00%
INVESCO INDIA CONTRA FUND & 1 OTHER WITH SAME PAN	Public	2.41%	2.41%	0.00%
VARSHA GOEL	Promoter	1.08%	1.08%	0.00%
MEGHA CHIRIPAL	Promoter	1.08%	1.08%	0.00%
BANDHAN HEALTHCARE FUND & 5 OTHER WITH SAME PAN	Public	1.04%	—	—
MANAS DHANUKA	Promoter	0.58%	0.58%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Orchid Pharma Limited	5,255	877.55	490.00	2.10%	+26.20% TTM	-87.41% TTM	+11.18%

Filings & corporate actions

Recent announcements

Announcement under regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A.24 Oct 2026 · Company Update / Press Release / Media Release
Outcome of Board Meeting for Raising Funds ("Enabling Resolution")20 Oct 2026 · Company Update / Raising of Funds
Outcome of Board Meeting20 Oct 2026 · Board Meeting / Outcome of Board Meeting
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting ....15 Oct 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 20189 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Scrutinizer''s Report and Voting Result-33rd Annual General Meeting of Orchid Pharma Limited3 Oct 2026 · AGM/EGM / AGM
Proceedings of 33rd Annual General Meeting of Orchid Pharma Limited Held on 29th September 202629 Sep 2026 · AGM/EGM / AGM
Intimation of Trading Window closure for Quarter-II of Financial Year 2026-27, ending on September 30, 2026.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation under regulation 30- Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation23 Sep 2026 · Company Update / General
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 201522 Sep 2026 · Company Update / General
Investor roadshow scheduled to be held in Mumbai21 Sep 2026 · Company Update / General
Annual Report of the Company for FY 2025-26.8 Sep 2026 · Others / Reg. 34 (1) Annual Report
Business Responsibility and Sustainability Report for FY 2025-268 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of 33rd Annual General Meeting of the Company7 Sep 2026 · AGM/EGM / AGM
Appointment of cost auditor for FY 2026-27 and change in designation of director.3 Sep 2026 · Company Update / Change in Management
Outcome of Board meeting.3 Sep 2026 · Others / Outcome without intimation
Transcript of Analysts/Investors earning call held with public at large on August 21, 2026.24 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording of the Analyst/Investor Earning Call for Q-1 ended on June 30, 202621 Aug 2026 · Company Update / Analyst / Investor Meet
Investors Presentation-Quarter 1 of F.Y.2026-27, ended on June 30, 2026.20 Aug 2026 · Company Update / Investor Presentation
Intimation of schedule of Analysts/Investors Earning call for the Quarter-1 ended on June 30, 2026.17 Aug 2026 · Company Update / Analyst / Investor Meet
Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.14 Aug 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Monitoring Agency Report for Quarter-1 of F.Y. 2026-27 ended June 30, 2026.14 Aug 2026 · Company Update / Monitoring Agency Report
Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of Merger14 Aug 2026 · Company Update / General
Financial Results for Quarter-1 of F.Y. 2026-27 ended on June 30, 2026.14 Aug 2026 · Result / Financial Results
Outcome of Board meeting inter alia for considering and approving Unaudited Financial Results for Quarter-1 of F.Y. 2026-27, ended on June 30, 2026.14 Aug 2026 · Board Meeting / Outcome of Board Meeting
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Limited reviewed financial ....11 Aug 2026 · Board Meeting / Board Meeting
Intimation under regulation 30- Update on scheme of Amalgamation1 Aug 2026 · Company Update / Allotment of Equity Shares
Outcome of Board Meeting held on August 01, 20261 Aug 2026 · Board Meeting / Outcome of Board Meeting
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting ....28 Jul 2026 · Board Meeting / Board Meeting
Intimation regarding Investor Roadshow25 Jul 2026 · Company Update / General
Confirmation certificate under Regulation 74(5) of Securities and Exchange board of India (Depositories and Participants) Regulations, 2018.11 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Fixation of Record Date pursuant to scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited for alloting shares to Shareholders of Dhanuka Laboratories Limited10 Jul 2026 · Corp. Action / Record Date
Outcome of Board Meeting: Amendment in the Capital Clause of Memorandum of Association of Company pursuant to the effectiveness of Scheme of Amalgamation of Dhanuka Laboratories Limited ....10 Jul 2026 · Company Update / Amendments to Memorandum & Articles of Association
Outcome of the Board Meeting10 Jul 2026 · Others / Outcome without intimation
Update related to the Scheme of Amalgamation of Dhanuka Laboratories Limited ("Amalgamating Company") with Orchid Pharma Limited ("Amalgamated Company/Company") and their respective Shareholders ....10 Jul 2026 · Company Update / General
Announcement under Regulation 30 regarding the licensing and supply agreement with Pharmasyntez JSC, Russia7 Jul 2026 · Company Update / Press Release / Media Release
Intimation of trading window closure for the Quarter-I of Financial Year 2026-27, ending on June 30, 202626 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Update for receipt of copy of order related to scheme of Amalgamation of Dhanuka Laboratories limited and Orchid Pharma limited12 Jun 2026 · Company Update / General
Disclosure regarding the order passed by Goods and Service Department.11 Jun 2026 · Company Update / Award of Order / Receipt of Order
In continuation to our earlier intimation dated March 18, 2026, with respect to merger petition, we would like to inform that Hon''ble National Company Law Tribunal ("NCLT") on June 05, ....5 Jun 2026 · Company Update / General

Board meetings

14 Aug 2026 Board Meeting - Financial Results